Trametinib (DMSO solvate)

Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis[1][2].

[1]Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with HWA486. Inflamm Res, 2012, 61(5), 445-454.|[2]Abe H, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med Chem Lett. 2011 Feb 28;2(4):320-4.Cancer Cell. 2020 Mar 16;37(3):387-402.e7. |Cell Rep. 2021 Jul 20;36(3):109410.|Cell Rep. 2023 Dec 18;42(12):113586.|Faculty of Biology, University of Barcelona. 2020 Jan.|Mol Cell. 2019 Jan 3;73(1):7-21.e7. |Patent. US20200046706A1.|Patent. US20210401844A1.|Patent. US20220162299A1.|Patent. US20220177583A1.|PLoS One. 2020 Sep 3;15(9):e0235824.|Sci Signal. 2018 Oct 30;11(554):eaar6795.|University of Leicester. 2023 Sep.|ACS Comb Sci. 2019 Dec 9;21(12):805-816.|Acta Pharmacol Sin. 2023 Feb 1.|Adv Healthc Mater. 2024 Oct 14:e2402685.|Adv Sci (Weinh). 2023 Mar 8;e2201164.|Am J Digest Dis. 2015;2(2):95-99.|Am J Respir Cell Mol Biol. 2019 Sep;61(3):355-366.|Anal Chem. 2024 Mar 8.|Angiogenesis. 2024 Jul 5.|Aquaculture. 2023 Sep 23, 740148.|Aquaculture. 2024 Oct 15.|Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489.|Biochem Biophys Res Commun. 2018 Jan 8;495(2):1846-1850. |Biomaterials. 16 September 2022.|Biomaterials. 2018 Sep;178:158-169.|Biomolecules. 2021 Mar 30;11(4):518.|Biomolecules. 2023 Apr 25, 13(5), 740.|bioRxiv. 2019 Sep.|bioRxiv. 2023 Oct 23.|bioRxiv. 2023 Oct 6.|bioRxiv. 2023 Sep 3.|bioRxiv. 2023 Sep 8.|bioRxiv. 2024 August 09.|bioRxiv. 2024 Dec 5:2024.11.29.625709.|bioRxiv. 2024 November 03.|bioRxiv. 2024 November 28.|bioRxiv. 2024 October 26.|bioRxiv. 2024 September 04.|bioRxiv. 2024 September 19.|bioRxiv. 2024 September 23.|Blood Cancer J. 2024 Aug 19;14(1):138.|Br J Cancer. 2023 May 17.|Cancer Biol Ther. 2019;20(5):653-665.|Cancer Cell. 2021 Aug 9;39(8):1135-1149.e8.|Cancer Cell. 2021 May 10;39(5):678-693.e11.|Cancer Cell. 2023 Dec 11;41(12):2083-2099.e9.|Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8.|Cancer Discov. 2012 Oct;2(10):934-47.|Cancer Discov. 2015 Sep;5(9):960-71.|Cancer Discov. 2018 Mar;8(3):354-369.|Cancer Discov. 2020 Aug;10(8):1226-1239.|Cancer Discov. 2020 Jun;10(6):872-887.|Cancer Immunol Res. 2020 Dec 10.|Cancer Lett. 2017 Nov 1;408:43-54. |Cancer Lett. 2024 Jun 5:217007.|Cancer Res. 2022 May 18;canres.4152.2021.|Cancer Res. 2024 Aug 13.|Cancers (Basel). 2022 Mar 11;14(6):1451.|Cancers (Basel). 2023 Apr 13, 15(8), 2280.|Cancers (Basel). 2024 Aug 7;16(16):2785.|Cancers. 2021 Feb 2;13(3):581.|Cell Biol Int. 2024 Sep 24.|Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.|Cell Death Differ. 2020 May;27(5):1520-1538. |Cell Death Dis. 2022 Oct 3;13(10):844.|Cell Death Discov. 2023 Sep 19;9(1):347.|Cell Metab. 2019 Jan 8;29(1):141-155.e9. |Cell Mol Life Sci. 2023 Mar 18;80(4):100.|Cell Oncol. 2022 Oct 21.|Cell Rep. 2019 Jul 2;28(1):119-131.e4. |Cell Signal. 2024 Sep 16:111415.|Cell Syst. 2019 Jul 24;9(1):35-48.e5. |Cell Syst. 2020 Jan 22;10(1):66-81.e11.|Cell Syst. 2020 Nov 18;11(5):478-494.e9.|Cell. 2024 Feb 1;187(3):624-641.e23.|Cell. 2024 Jan 4;187(1):166-183.e25.|Cell. 2018 Aug 9;174(4):843-855.e19.|Cells. 2022, 11(15), 2402.|Clin Cancer Res. 2014 Nov 1;20(21):5483-95. |Clin Cancer Res. 2022 Jul 7;ccr.22.1052.|Clin Cancer Res. 2023 Jan 17;CCR-22-1973.|Comput Struct Biotechnol J. 2019 Feb 8;17:352-361.|Dis Model Mech. 2023 Mar 2;dmm.049769.|EBioMedicine. 2020 Jan;51:102583.|EBioMedicine. 2022 Dec 8;87:104397.|Endocrinology. 2024 Sep 16.|Eur J Cancer. 2018 Aug;99:37-48.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Exp Mol Med. 2023 Oct 2.|FEBS Lett. 2024 Oct 20.|Front Cell Dev Biol. 2018 Sep 25;6:111.|Front Oncol. 2021 Jul 13;11:704042.|Genes Dis. 1 July 2021.|Geroscience. 2023 Sep 26.|Harvard Medical School LINCS LIBRARY|Inflammation. 2023 May 12.|Int J Cancer. 2019 Mar 15;144(6):1379-1390.|Int J Mol Sci. 2022 Nov 19;23(22):14385.|Int J Mol Sci. 2022, 23(19), 11939.|Int J Mol Sci. 2022, 23(20), 12587.|Int J Mol Sci. 2023 Mar 13.|J Cardiothorac Surg. 2021 May 10;16(1):127.|J Cell Biochem. 2016 Jun;117(6):1340-51. |J Cell Sci. 2019 May 31;132(11):jcs224071. |J Clin Invest. 2022 Nov 22;e153470.|J Clin Toxicol 2014, 4:5|J Clin Toxicol. 2014 October 4, 4:5.|J Exp Clin Cancer Res. 2018 Sep 5;37(1):218.|J Exp Clin Cancer Res. 2023 Apr 19;42(1):92.|J Exp Clin Cancer Res. 2024 Jun 18;43(1):171.|J Exp Med. 2024 Mar 4;221(3):e20232028.|J Hepatol. 2021 Aug;75(2):363-376.|J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9.|J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8.|J Transl Med. 2022 Jun 7;20(1):263.|J Transl Med. 2023 Jan 9;21(1):9.|J Transl Med. 2024 May 13;22(1):450.|J Vasc Res. 2023 Feb 2.|JCO Precis Oncol. 2024 Apr:8:e2300538.|Leuk Lymphoma. 2021 Feb;62(2):337-347.|Mbio. 2024 Jan 23:e0319723.|medRxiv. 2023 Nov 13.|Mil Med Res. 2023 Dec 20;10(1):68.|Mol Cancer Ther. 2016 Aug;15(8):1859-69. |Mol Cancer. 2023 May 20;22(1):86.|Mol Cancer. 2024 Sep 20;23(1):204.|Mol Carcinog. 2024 Apr 17|Mol Pharmacol. 2019 Dec;96(6):862-870.|Mol Psychiatry. 2022 Aug 10.|Mol Syst Biol. 2023 Dec 18.|Mol Ther Nucleic Acids. 2024 Jul 19;35(3):102283.|Nat Biomed Eng. 2018 Aug;2(8):578-588.|Nat Cell Biol. 2023 Jan 12.|Nat Commun. 2020 Aug 13;11(1):4053.|Nat Commun. 2020 May 11;11(1):2333.|Nat Commun. 2020 Oct 29;11(1):5463.|Nat Commun. 2021 Aug 25;12(1):5058.|Nat Commun. 2023 May 19;14(1):2859.|Nat Commun. 2024 Mar 21;15(1):2551.|Nat Commun. 2024 May 7;15(1):3805.|Nat Commun. 2019 Jan 17;10(1):296.|Neuro Oncol. 2019 Mar 18;21(4):486-497. |Oncogene. 2024 May 17.|Oncogenesis. 2019 Nov 4;8(11):65. |Oncol Lett. 2017 Dec;14(6):6863-6868.|Oncol Lett. December 17, 2021.|Oncol Rep. 2018 Dec; 40(6): 3313–3322.|Oncotarget. 2015 Oct 13;6(31):31313-22. |Oncotarget. 2017 Feb 28;8(9):14835-14846. |Oncotarget. 2020 Nov 3;11(44):3921-3932.|Patent. US20180161326A1.|Patent. US20180169102A1.|Patent. US20180291421A1.|Patent. US20200276189A1.|Patent. US20200291111A1.|Patent. US20200308623A1.|Patent. US20200354680A1.|Patent. US20210008047A1.|Patent. US20210010089A1.|Patent. US20220265657A1.|Patent. US20220372134A1.|Patent. US20230049752A1.|Patent. US20230068698A1.|Patent. US20230158019A1.|Patent. US20240140945A1.|Patent. US20240239801A1.|Patent. US20240366605A1.|Patent. WO2019056023A2.|Phytomedicine. 2023 Nov 11, 155208.|PLoS Biol. 2020 Jul 17;18(7):e3000778.|Preprints. 2024 Jul 8.|Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9570-E9579. |Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4508-4517.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2023 Jul 10.|Research Square Preprint. 2023 May 16.|Research Square Preprint. 2024 Nov 03.|Research Square Preprint. 2024 Nov 06.|Research Square Preprint. 2024 Nov 26.|Research Square Print. October 10th, 2022.|Sci Data. 2024 Sep 19.|Sci Rep. 2016 Oct 19;6:35531.|Sci Rep. 2017 Mar 28;7:45332.|Sci Rep. 2022 Nov 5;12(1):18811.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.|SSRN. 2023 Aug 9.|Stem Cell Reports. 2016 Jan 12;6(1):74-84.|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.|Technical University of Munich. 2024.|Theranostics. 2022 Oct 3;12(16):7051-7066.|Theranostics. 2020 Feb 18;10(8):3579-3593. |Toxicology. 2024 Apr 17:153807.|University of California. 2023 Feb.|University of Düsseldorf. 2024.|University of Puerto Rico. 2024 Jun.|Vet J. 2024 Dec.|Viruses. 2021, 13(9), 1758.